Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- KDNY
- Price
- -
- Stock movement up
- +- (%)
- Company name
- Chinook Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 2.71B
- Ent value
- 2.71B
- Price/Sales
- 463.01
- Price/Book
- 7.58
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- 86.90%
- 3 year return
- -14.22%
- 5 year return
- -21.44%
- 10 year return
- -
Last updated: 2024-12-17
DIVIDENDS
KDNY does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 463.01 |
| Price to Book | 7.58 |
| EV to Sales | 463.80 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 67.05M |
| EPS (TTM) | -3.40 |
| FCF per share (TTM) | -0.83 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 5.85M |
| Gross profit (TTM) | 4.12M |
| Operating income (TTM) | -251.63M |
| Net income (TTM) | -243.21M |
| EPS (TTM) | -3.40 |
| EPS (1y forward) | -3.60 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 70.49% |
| Operating margin (TTM) | -4302.07% |
| Profit margin (TTM) | -4158.15% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 127.15M |
| Net receivables | 3.10M |
| Total current assets | 305.42M |
| Goodwill | 117.00K |
| Intangible assets | 59.97M |
| Property, plant and equipment | 0.00 |
| Total assets | 488.81M |
| Accounts payable | 16.36M |
| Short/Current long term debt | 33.98M |
| Total current liabilities | 52.47M |
| Total liabilities | 131.77M |
| Shareholder's equity | 357.04M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -174.00M |
| Capital expenditures (TTM) | 2.60M |
| Free cash flow (TTM) | -59.52M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -68.12% |
| Return on Assets | -49.76% |
| Return on Invested Capital | -67.31% |
| Cash Return on Invested Capital | -16.47% |
STOCK INFORMATION
Downside potential
Loading...
Downside potential data
| KDNY | S&P500 | |
| Current price drop from All-time high | -96.23% | -8.63% |
| Highest price drop | -99.00% | -56.47% |
| Date of highest drop | 25 Oct 2021 | 9 Mar 2009 |
| Avg drop from high | -84.10% | -10.99% |
| Avg time to new high | 1052 days | 12 days |
| Max time to new high | 2099 days | 1805 days |
COMPANY DETAILS
Marketcap
2.71B
Marketcap category
Mid-cap
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington. As of August 11, 2023, Chinook Therapeutics, Inc. operates as a subsidiary of Novartis AG.
Employees
214
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner